Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04254549 · ClinicalTrials.gov registry record · Phase 2
Rifaximin in Patients With Diabetic Gastroparesis
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04254549: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT04254549 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04254549, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
Interventions
- DRUG Placebo
- DRUG Rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-06-14 |
| Est. Completion | 2025-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04254549
The ClinicalTrials.gov registry entry for NCT04254549 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04254549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04254549 about?
NCT04254549 is a clinical study titled "Rifaximin in Patients With Diabetic Gastroparesis". Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
What is the current status of trial NCT04254549?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-06-14. Estimated completion is 2025-04-11.
What interventions are being tested in trial NCT04254549?
The interventions under investigation include: Placebo (DRUG), Rifaximin (DRUG).
Who is sponsoring clinical trial NCT04254549?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.